Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
29 août 2024 09h17 HE
|
Vericel Corporation
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
26 août 2024 07h45 HE
|
Vericel Corporation
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI’s $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 ...
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
15 août 2024 16h05 HE
|
Vericel Corporation
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in...
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
07 août 2024 08h30 HE
|
Vericel Corporation
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports Second Quarter 2024 Financial Results
01 août 2024 07h55 HE
|
Vericel Corporation
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% ...
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
22 juil. 2024 08h30 HE
|
Vericel Corporation
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the...
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
18 juil. 2024 08h30 HE
|
Vericel Corporation
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it...
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
11 juin 2024 08h30 HE
|
Vericel Corporation
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
22 mai 2024 08h30 HE
|
Vericel Corporation
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick...
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
08 mai 2024 07h55 HE
|
Vericel Corporation
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance...